Avid Bioservices Inc (CDMO)

[entdoc]

Until 2000: The investigational human monoclonal antibodies (hMAb) M9, 2F5, and 2G12 recognize cell surface docking sites that are mostly glycoproteins. "Glyco-" (glycogen=starch=carbohydrate) and protein. Bavituximab targets a fat-laden docking site. The subject antibodies are thought to act by inhibiting the attachment and entry of HIV viruses into susceptible cells. Bavituximab action interferes with viral capsule formation at exit from the cell, and encourages enhanced immune response. Sounds like the two groups might be synergistic. Also, I am sure that there is intense efforts to engineer a smaller, more streamlined Bavi. All the above is mostly guesswork. Don't take it to the bank. I am still learning too!